Kingsley Capital Partners

QuantifiedESG is a company that specializes in developing assessment and rating tools focused on environmental, social, and governance (ESG) evaluations. Its platform quantitatively analyzes various social and environmental risk factors, producing comprehensive ESG evaluation reports. These reports assess the level of business management relative to the risks associated with the company's operations and assets. By providing these insights, QuantifiedESG enables clients to evaluate the sustainability of their supply chains and make informed decisions regarding their investment and operational strategies.

Spring Fibre is a London-based operator of fiber optics networks that specializes in providing high-speed internet services. The company focuses on developing robust infrastructure to support retailers in delivering reliable broadband, particularly in underpenetrated and hard-to-reach areas. By offering wholesale provision of fiber networks, Spring Fibre aims to enhance connectivity and accessibility in regions where internet service is limited.

Atlas Tower Group is a provider of wireless infrastructure solutions, specializing in the design and development of towers and rooftops that are ready for 5G technology. The company focuses on acquiring telecommunication sites and offers installation and integration services for active infrastructure. By accommodating the needs of multiple tenants, Atlas Tower Group enables mobile network operators to meet the growing demand for enhanced coverage and capacity in the telecommunications sector.

Equinox International is a cannabis company that specializes in developing pharmaceutical-quality products. It operates as a vertically integrated entity, managing the entire process from cultivation to branding. The company focuses on creating a diverse array of medical cannabis offerings, including oils, tinctures, tonics, tablets, capsules, creams, and lotions. These products are designed to cater to various medical needs and lifestyle preferences, allowing clients to select options that best suit their specific indications.

Oxford Cannabinoid Technologies Ltd. is a biopharmaceutical company based in Oxford, United Kingdom, dedicated to the research and development of cannabinoid-based compounds and therapies. Established in 2017, the company aims to address various medical conditions, including inflammatory diseases, oncology, neurological disorders, and pain management. It employs a drug development approach that incorporates proprietary cannabinoid derivatives, natural phytocannabinoids, and in-licensed compounds. The company's primary focus is on the pain market, with plans to develop a portfolio of drug candidates intended for regulatory approval as licensed pain medications, all while collaborating with leading medical researchers to meet high unmet medical needs.